{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:35:05Z","timestamp":1791891305370,"version":"4.3.4"},"reference-count":137,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2013,7,6]],"date-time":"2013-07-06T00:00:00Z","timestamp":1373068800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Sports Med"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s40279-013-0075-4","type":"journal-article","created":{"date-parts":[[2013,7,5]],"date-time":"2013-07-05T13:19:27Z","timestamp":1373030367000},"page":"965-977","source":"Crossref","is-referenced-by-count":20,"title":["From Gene Engineering to Gene Modulation and Manipulation: Can We Prevent or Detect Gene Doping in Sports?"],"prefix":"10.1007","volume":"43","author":[{"given":"Giuseppe","family":"Fischetto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Bermon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,7,6]]},"reference":[{"key":"75_CR1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nbt.1769","volume":"29","author":"C Sheridan","year":"2011","unstructured":"Sheridan C. Gene therapy finds its niche. Nat Biotechnol. 2011;29:121\u20138.","journal-title":"Nat Biotechnol"},{"key":"75_CR2","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1590\/S0100-879X2011007500145","volume":"44","author":"RS Oliveira","year":"2011","unstructured":"Oliveira RS, Collares TF, Smith KR, et al. The use of genes for performance enhancement: doping or therapy? Braz J Med Biol Res. 2011;44:1194\u2013201.","journal-title":"Braz J Med Biol Res"},{"key":"75_CR3","unstructured":"Cummiskey J. Report on the IOC MC gene therapy medicine and sport. Lausanne: IOC; 2002."},{"key":"75_CR4","unstructured":"Haisma HJ. Gene doping. Review. Netherland Centre for Doping Affairs. 2004."},{"key":"75_CR5","unstructured":"WADA prohibited list. http:\/\/www.wada-ama.org\/en\/World-Anti-Doping-Program\/Sports-and-Anti-Doping-Organizations\/International-Standards\/Prohibited-List\/ . Accessed 30 June 2013."},{"key":"75_CR6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/jgm.344","volume":"5","author":"J Huard","year":"2003","unstructured":"Huard J, Li Y, Peng HR, et al. Gene therapy and tissue engineering for sports medicine. J Gene Med. 2003;5:93\u2013108.","journal-title":"J Gene Med"},{"key":"75_CR7","first-page":"33","volume":"19","author":"JM Alonso","year":"2004","unstructured":"Alonso JM. Methods to increase the delivery of oxygen. New Stud Athl. 2004;19:33\u201343.","journal-title":"New Stud Athl"},{"key":"75_CR8","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/00007256-200333030-00003","volume":"33","author":"A Gaudard","year":"2003","unstructured":"Gaudard A, Varlet-Marie E, Bressolle F, et al. Drugs for increasing oxygen transport and their potential use in doping. Sports Med. 2003;33:187\u2013212.","journal-title":"Sports Med"},{"key":"75_CR9","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1097\/00005768-199905000-00012","volume":"31","author":"MA Rivera","year":"1999","unstructured":"Rivera MA, Perusse L, Simoneau JA, et al. Linkage between a muscle specific creatine kinase gene polymorphism and VO2 max in the HERITAGE Family study. Med Sci Sports Exerc. 1999;31:698\u2013701.","journal-title":"Med Sci Sports Exerc"},{"key":"75_CR10","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1097\/00005768-200010000-00008","volume":"32","author":"B Wolfarth","year":"2000","unstructured":"Wolfarth B, Rivera MA, Oppert IM, et al. A polymorphism in the alpha2a-adrenoceptor gene and endurance athlete status. Med Sci Sports Exerc. 2000;32:1709\u201312.","journal-title":"Med Sci Sports Exerc"},{"key":"75_CR11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1249\/MSS.0b013e3181844179","volume":"41","author":"MS Bray","year":"2009","unstructured":"Bray MS, Hagberg JM, P\u00e9russe L, et al. The human gene map for performance and health related fitness phenotypes. The 2006\u20132007 update. Med Sci Sports Exerc. 2009;41:34\u201372.","journal-title":"Med Sci Sports Exerc"},{"key":"75_CR12","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1249\/MSS.0b013e3181d86cec","volume":"42","author":"T Rankinen","year":"2010","unstructured":"Rankinen T, Roth SM, Bray SM, et al. Advances in exercise, fitness and performance genomics. Med Sci Sports Exerc. 2010;42:835\u201346.","journal-title":"Med Sci Sports Exerc"},{"key":"75_CR13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00421-006-0154-4","volume":"97","author":"II Ahmetov","year":"2006","unstructured":"Ahmetov II, Mozhayskaya IA, Flavell DM, et al. PPAR-alfa gene variation and physical performance in Russian athletes. Eur J Appl Physiol. 2006;97:103\u20138.","journal-title":"Eur J Appl Physiol"},{"key":"75_CR14","first-page":"41","volume":"20","author":"G Fischetto","year":"2005","unstructured":"Fischetto G. New trends in gene doping. New Stud Athl. 2005;20:41\u20139.","journal-title":"New Stud Athl"},{"key":"75_CR15","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1080\/17511320701425181","volume":"2","author":"A Miah","year":"2007","unstructured":"Miah A. Genetics, bioethics and sport. Sport Ethics Philos. 2007;2:146\u201358.","journal-title":"Sport Ethics Philos"},{"key":"75_CR16","unstructured":"The Stockholm Declaration (2005). http:\/\/www.wada-ama.org\/en\/Science-Medicine\/Scientific-Events\/Stockholm-Symposium-Agenda-and-Presentation-2005\/Stockholm-Declaration\/ . Accessed 30 June 2013."},{"key":"75_CR17","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1086\/377590","volume":"73","author":"N Yang","year":"2003","unstructured":"Yang N, Mac Arthur DG, Gulbin JP, et al. ACTN3 genotype is associated with human elite athletic performance. Am J Hum Genet. 2003;73:627\u201331.","journal-title":"Am J Hum Genet."},{"key":"75_CR18","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/bjsm.2006.034199","volume":"41","author":"A Lucia","year":"2007","unstructured":"Lucia A, Oliv\u00e0n J, G\u00f2mez Gallego F, et al. Citius and longius (faster and longer) with no alpha-actinin-3 in skeletal muscles? Br J Sports Med. 2007;41:616\u20137.","journal-title":"Br J Sports Med."},{"key":"75_CR19","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/13573320600813432","volume":"11","author":"A Miah","year":"2006","unstructured":"Miah A, Rich E. Genetic test for ability? Talent identification and the value of an open future. Sport Educ Soc. 2006;11:259\u201373.","journal-title":"Sport Educ Soc"},{"key":"75_CR20","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2165\/00007256-200939050-00001","volume":"39","author":"MJ McNamee","year":"2009","unstructured":"McNamee MJ, Muller A, van Hilvoorde I, et al. Genetic testing and sports medicine ethics. Sports Med. 2009;39:339\u201344.","journal-title":"Sports Med"},{"key":"75_CR21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/1741826710389924","volume":"18","author":"D Corrado","year":"2011","unstructured":"Corrado D, Drezner J, Basso C, et al. Strategies for the prevention of sudden cardiac death during sports. Eur J Cardiovasc Prev Rehabil. 2011;18:197\u2013208.","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"75_CR22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.csm.2007.09.004","volume":"17","author":"F Pigozzi","year":"2008","unstructured":"Pigozzi F, Rizzo M. Sudden death in competitive athletes. Clin Sports Med. 2008;17:153\u201381.","journal-title":"Clin Sports Med"},{"key":"75_CR23","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1056\/NEJMra022783","volume":"11","author":"BJ Maron","year":"2003","unstructured":"Maron BJ. Sudden death in young athletes. N Engl J Med. 2003;11:1064\u201375.","journal-title":"N Engl J Med"},{"key":"75_CR24","first-page":"502","volume":"94","author":"CJ Garratt","year":"2008","unstructured":"Garratt CJ. Clinical indications for genetic testing in familial sudden cardiac death syndromes. Heart. 2008;94:502\u20137.","journal-title":"Heart"},{"key":"75_CR25","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/scientificamerican0704-62","volume":"291","author":"HL Sweeney","year":"2004","unstructured":"Sweeney HL. Gene doping. Sci Am. 2004;291:63\u20139.","journal-title":"Sci Am"},{"key":"75_CR26","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/30374","volume":"393","author":"HE Montgomery","year":"1998","unstructured":"Montgomery HE, Marshall R, Hemingway H, et al. Human gene for physical performance. Nature. 1998;393:221\u20132.","journal-title":"Nature"},{"key":"75_CR27","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2165\/11593200-000000000-00000","volume":"41","author":"Z Puthucheary","year":"2011","unstructured":"Puthucheary Z, Skipworth JRA, Rawal J, et al. Genetic influence in sport and physical performance. Sports Med. 2011;41:845\u201359.","journal-title":"Sports Med"},{"key":"75_CR28","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ymthe.2004.08.004","volume":"10","author":"IM Verma","year":"2004","unstructured":"Verma IM. Doping, gene transfer and sport. Mol Ther. 2004;10:405.","journal-title":"Mol Ther"},{"key":"75_CR29","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.pcl.2007.04.004","volume":"54","author":"GR Gaffney","year":"2007","unstructured":"Gaffney GR, Parisotto R. Gene doping: a review of performance-enhancing genetics. Pediatr Clin N Am. 2007;54:807\u201322.","journal-title":"Pediatr Clin N Am"},{"issue":"Suppl 1","key":"75_CR30","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0140-6736(05)67829-4","volume":"366","author":"S Pincock","year":"2005","unstructured":"Pincock S. Feature: gene doping. Lancet. 2005;366(Suppl 1):18\u20139.","journal-title":"Lancet"},{"key":"75_CR31","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/bjsm.2004.013623","volume":"38","author":"G Lippi","year":"2004","unstructured":"Lippi G, Guidi GC. Gene manipulation and improvement of athletic performance: new strategies in blood doping. Br J Sports Med. 2004;38:641.","journal-title":"Br J Sports Med"},{"key":"75_CR32","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.clinbiochem.2009.01.001","volume":"12","author":"HME Azzazy","year":"2009","unstructured":"Azzazy HME, Mansour MMH, Christenson RH. Gene doping: of mice and men. Clin Biochem. 2009;12:435\u201341.","journal-title":"Clin Biochem"},{"key":"75_CR33","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.clinbiochem.2005.09.007","volume":"38","author":"HME Azzazy","year":"2005","unstructured":"Azzazy HME, Mansour MMH, Christenson RH. Doping in the recombinant era: strategies and counterstrategies. Clin Biochem. 2005;38:959\u201365.","journal-title":"Clin Biochem"},{"key":"75_CR34","first-page":"S352","volume":"9","author":"E Brill-Almon","year":"2004","unstructured":"Brill-Almon E, Pearlman A, Stern B, et al. Biopump: a novel approach to gene-mediated protein production and delivery with application for erythropoietin treatment of anemia. Mol Ther. 2004;9:S352\u20133.","journal-title":"Mol Ther"},{"key":"75_CR35","unstructured":"Novel sustained delivery of erythropoietin in hemodialysis patients for safer anemia control using EPODURE\u2122 Biopumps\u2014autologous dermal tissue samples secreting erythropoietin. Poster presented at the American Society of Nephrology\u2019s Kidney Week 2012, San Diego."},{"key":"75_CR36","first-page":"46","volume":"14","author":"W Wang","year":"2013","unstructured":"Wang W, Li W, Ma N, et al. Non-viral gene delivery methods. Curr Pharm Biotechnol. 2013;14:46\u201360.","journal-title":"Curr Pharm Biotechnol."},{"key":"75_CR37","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/sj.gt.3302570","volume":"12","author":"PL Sinn","year":"2005","unstructured":"Sinn PL, Sauter SL, McCray PB Jr. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors\u2014design, biosafety, and production. Gene Ther. 2005;12:1089\u201398.","journal-title":"Gene Ther"},{"key":"75_CR38","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2174\/092986712803414141","volume":"19","author":"M Jafari","year":"2012","unstructured":"Jafari M, Soltani M, Naahidi S, et al. Nonviral approach for targeted nucleic acid delivery. Curr Med Chem. 2012;19:197\u2013208.","journal-title":"Curr Med Chem."},{"key":"75_CR39","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1126\/science.1177801","volume":"327","author":"T Friedman","year":"2010","unstructured":"Friedman T, Rabin O, Frankel MS. Gene doping and sport. Science. 2010;327:647\u20138.","journal-title":"Science"},{"key":"75_CR40","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1136\/bjsm.37.3.192","volume":"37","author":"P McCrory","year":"2003","unstructured":"McCrory P. Super athletes or gene cheats? Br J Sports Med. 2003;37:192\u20133.","journal-title":"Br J Sports Med"},{"key":"75_CR41","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/bjp.2008.144","volume":"154","author":"DJ Wells","year":"2008","unstructured":"Wells DJ. Gene doping: the hype and the reality. Br J Pharmacol. 2008;154:623\u201331.","journal-title":"Br J Pharmacol"},{"key":"75_CR42","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/ng0693-108","volume":"4","author":"GD Longmore","year":"1993","unstructured":"Longmore GD. Erythropoietin receptor mutations and Olympic glory. Nat Genet. 1993;4:108\u201310.","journal-title":"Nat Genet"},{"key":"75_CR43","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/0140-6736(93)92558-B","volume":"341","author":"A Chapelle de la","year":"1993","unstructured":"de la Chapelle A, Sistonen P, Lehvaslaiho H, et al. Familial erythrocytosis genetically linked to erythropoietin receptor gene. Lancet. 1993;341:82\u20134.","journal-title":"Lancet"},{"key":"75_CR44","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1182\/blood.V78.11.3066.3066","volume":"78","author":"E Juvonen","year":"1991","unstructured":"Juvonen E, Ikkala E, Fyhrquist F, et al. Autosomal dominant erythrocytosis caused by increased sensitivity to erythropoietin. Blood. 1991;78:3066\u20139.","journal-title":"Blood"},{"key":"75_CR45","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1182\/blood.V89.6.2148","volume":"6","author":"A Sergeyeva","year":"1997","unstructured":"Sergeyeva A, Gordeuk VR, Tokarev YN, et al. Congenital polycythemia in Chuvashia. Blood. 1997;6:2148\u201354.","journal-title":"Blood"},{"key":"75_CR46","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/ng1019","volume":"32","author":"SO Ang","year":"2002","unstructured":"Ang SO, Chen H, Hirota K, et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet. 2002;32:614\u201321.","journal-title":"Nat Genet"},{"key":"75_CR47","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","volume":"356","author":"LM Scott","year":"2007","unstructured":"Scott LM, Tong W, Levine RL, et al. JAK2 Exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459\u201368.","journal-title":"N Engl J Med"},{"key":"75_CR48","doi-asserted-by":"crossref","first-page":"831","DOI":"10.2165\/00007256-200535100-00001","volume":"35","author":"E Diamanti-Kandarakis","year":"2005","unstructured":"Diamanti-Kandarakis E, Konstantinopoulos PA, Papailiou J, et al. Erythropoietin abuse and erythropoietin gene doping. Detection strategies in the genomic era. Sports Med. 2005;35:831\u201340.","journal-title":"Sports Med"},{"key":"75_CR49","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/35015164","volume":"405","author":"F Lasne","year":"2000","unstructured":"Lasne F, de Ceaurriz J. Recombinant erythropoietin in urine. Nature. 2000;405:635.","journal-title":"Nature"},{"key":"75_CR50","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2165\/00007256-200232020-00004","volume":"32","author":"RL Wilber","year":"2002","unstructured":"Wilber RL. Detection of DNA-recombinant human epoetin-alfa as a pharmacological ergogenic aid. Sports Med. 2002;32:125\u201342.","journal-title":"Sports Med"},{"key":"75_CR51","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.cca.2007.01.014","volume":"379","author":"S Lamon","year":"2007","unstructured":"Lamon S, Robinson N, Mangin P, et al. Detection window of darbepoetin-alpha following one single subcutaneous injection. Clin Chim Acta. 2007;379:145\u20139.","journal-title":"Clin Chim Acta."},{"key":"75_CR52","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1152\/japplphysiol.01102.2009","volume":"108","author":"T Maerken Van","year":"2010","unstructured":"Van Maerken T, Dhondt A, Delanghe JR. A rapid and simple assay to determine pegylated erythropoietin in human serum. J Appl Physiol. 2010;108:800\u20133.","journal-title":"J Appl Physiol."},{"key":"75_CR53","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.forsciint.2011.07.012","volume":"213","author":"N Leuenberger","year":"2011","unstructured":"Leuenberger N, Saugy J, Mortensen RB, et al. Methods for detection and confirmation of Hematide\u2122\/peginesatide in anti-doping samples. Forensic Sci Int. 2011;213:15\u20139.","journal-title":"Forensic Sci Int."},{"key":"75_CR54","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0003-2697(02)00407-4","volume":"311","author":"F Lasne","year":"2002","unstructured":"Lasne F, Martin L, Crepin N. Detection of isoelectric profiles of erythropoietin in urine: differentiation of natural and administered recombinant hormones. Anal Biochem. 2002;311:119\u201326.","journal-title":"Anal Biochem"},{"key":"75_CR55","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1002\/elps.200600363","volume":"28","author":"F Lasne","year":"2007","unstructured":"Lasne F, Thioulouse J, Martin L, et al. Detection of recombinant erythropoietin in urine for doping analysis: interpretation of isoelectric profiles by discriminant analysis. Electrophoresis. 2007;28:1875\u201381.","journal-title":"Electrophoresis"},{"key":"75_CR56","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3324\/haematol.2009.006809","volume":"94","author":"F Lasne","year":"2009","unstructured":"Lasne F, Martin L, Martin JA, et al. Detection of continuous erythropoietin receptor activator in blood and urine in anti-doping controls. Haematologica. 2009;94:888\u201390.","journal-title":"Haematologica"},{"key":"75_CR57","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1089\/hum.1997.8.15-1797","volume":"8","author":"E Svensson","year":"1997","unstructured":"Svensson E, Black HB, Dugger DLI, et al. Long term erythropoietin expression in rodent and non human primates following intramuscular injection of a replication defective adenoviral vector. Hum Gene Ther. 1997;8:1797\u2013806.","journal-title":"Hum Gene Ther"},{"key":"75_CR58","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/sj.gt.3300648","volume":"5","author":"S Zhou","year":"1998","unstructured":"Zhou S, Murphy JE, Escobedo JA, et al. Adeno-associated virus-mediated delivery of erythropoietin leads to sustained elevation of haematocrit in non human primates. Gene Ther. 1998;5:665\u201370.","journal-title":"Gene Ther"},{"key":"75_CR59","first-page":"594","volume":"98","author":"D Bohl","year":"1998","unstructured":"Bohl D, Salvetti A, Moullier P, et al. Control of erythropoietin delivery by doxycycline in mice after intramuscular injection of adeno-associated vector. Blood. 1998;98:594\u20136.","journal-title":"Blood"},{"key":"75_CR60","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1006\/mthe.2002.0646","volume":"6","author":"B Sommer","year":"2002","unstructured":"Sommer B, Rinsch C, Payen E, et al. Long term doxycycline regulated secretion of erythropoietin by encapsulated myoblasts. Mol Ther. 2002;6:155\u201361.","journal-title":"Mol Ther"},{"key":"75_CR61","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1681\/ASN.2010010116","volume":"21","author":"WM Bernhardt","year":"2010","unstructured":"Bernhardt WM, Wiesener M, Scigalla P, et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol. 2010;21:2151\u20136.","journal-title":"J Am Soc Nephrol."},{"key":"75_CR62","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1158\/1078-0432.CCR-10-2577","volume":"17","author":"BD Hedley","year":"2011","unstructured":"Hedley BD, Allan AL, Xenocostas A. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression. Clin Cancer Res. 2011;17:6373\u201380.","journal-title":"Clin Cancer Res"},{"key":"75_CR63","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1182\/blood-2006-08-019083","volume":"109","author":"HF Bunn","year":"2007","unstructured":"Bunn HF. New agents that stimulate erythropoiesis. Blood. 2007;109:868\u201373.","journal-title":"Blood"},{"key":"75_CR64","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1056\/NEJMcibr035011","volume":"348","author":"JT Prchal","year":"2003","unstructured":"Prchal JT. Delivery on demand. A new era of gene therapy? N Engl J Med. 2003;348:1282\u20133.","journal-title":"N Engl J Med"},{"key":"75_CR65","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2002-02-0605","volume":"100","author":"K Binley","year":"2002","unstructured":"Binley K, Iqball S, Spearman H, et al. Long-term reversal of chronic anemia using a hypoxia-regulated erythropoietin gene therapy. Blood. 2002;100:2406\u201313.","journal-title":"Blood"},{"key":"75_CR66","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2174\/1566523034578131","volume":"3","author":"L Tenenbaum","year":"2003","unstructured":"Tenenbaum L, Lehtonen E, Monaham PE. Evaluation of risks related to the use of adeno-associated virus based vectors. Curr Gene Ther. 2003;3:545\u201365.","journal-title":"Curr Gene Ther"},{"key":"75_CR67","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1182\/blood-2003-11-3845","volume":"103","author":"P Chenuaud","year":"2004","unstructured":"Chenuaud P, Larcher T, Rabinowitz JE, et al. Autoimmune anemia in macaques following erythropoietin gene therapy. Blood. 2004;103:3303\u20134.","journal-title":"Blood"},{"key":"75_CR68","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1182\/blood-2003-11-3852","volume":"103","author":"G Gao","year":"2004","unstructured":"Gao G, Lebherz C, Weiner DJ, et al. Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood. 2004;103:3300\u20132.","journal-title":"Blood"},{"key":"75_CR69","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ymthe.2004.07.024","volume":"10","author":"F Lasne","year":"2004","unstructured":"Lasne F, Martin L, de Ceaurriz J, et al. \u201cGenetic doping\u201d with erythropoietin cDNA in primate muscle is detectable. Mol Ther. 2004;10:409\u201310.","journal-title":"Mol Ther"},{"key":"75_CR70","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1373\/clinchem.2011.162271","volume":"67","author":"PE Sottas","year":"2011","unstructured":"Sottas PE, Robinson N, Rabin O, et al. The athlete biological passport. Clin Chem. 2011;67:969\u201376.","journal-title":"Clin Chem"},{"key":"75_CR71","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.forsciint.2011.07.029","volume":"213","author":"J Segura","year":"2011","unstructured":"Segura J, Ventura R, Pascual JA. Current strategic approaches for the detection of blood doping practices. Forensic Sci Intern. 2011;213:42\u20138.","journal-title":"Forensic Sci Intern"},{"key":"75_CR72","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/lpr\/mgm042","volume":"7","author":"PE Sottas","year":"2008","unstructured":"Sottas PE, Robinson N, Saugy M, et al. A forensic approach to the interpretation of blood doping markers. Law Probab Risk. 2008;7:191\u2013210.","journal-title":"Law Probab Risk"},{"key":"75_CR73","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1373\/clinchem.2010.156067","volume":"57","author":"PE Sottas","year":"2011","unstructured":"Sottas PE, Robinson N, Fischetto G, et al. Prevalence of blood doping in samples collected from elite track and field athletes. Clin Chem. 2011;57:762\u20139.","journal-title":"Clin Chem"},{"key":"75_CR74","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00007691-200404000-00016","volume":"26","author":"JA Pascual","year":"2004","unstructured":"Pascual JA, Belalcazar V, de Bolos C, et al. Recombinant erythropoietin and analogues: a challenge for doping control. Ther Drug Monit. 2004;26:175\u20139.","journal-title":"Ther Drug Monit"},{"key":"75_CR75","first-page":"356","volume":"91","author":"K Sharpe","year":"2006","unstructured":"Sharpe K, Ashenden MJ, Schumacher YO. A third generation approach to detect erythropoietin abuse in athletes. Haematologica. 2006;91:356\u201363.","journal-title":"Haematologica"},{"key":"75_CR76","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1152\/advan.00052.2006","volume":"30","author":"H Liang","year":"2006","unstructured":"Liang H, Ward WF. PGC-1 alpha. A key regulator of energy metabolism. Adv Physiol Educ. 2006;30:145\u201351.","journal-title":"Adv Physiol Educ"},{"key":"75_CR77","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/bjp.2008.163","volume":"154","author":"M Spedding","year":"2008","unstructured":"Spedding M, Spedding C. Drugs in sport: a scientist-athlete\u2019s perspective: from ambition to neurochemistry. Br J Pharmacol. 2008;154:496\u2013501.","journal-title":"Br J Pharmacol"},{"key":"75_CR78","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2006.11.013","volume":"127","author":"M Lagouge","year":"2006","unstructured":"Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1a. Cell. 2006;127:1109\u201322.","journal-title":"Cell"},{"key":"75_CR79","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s12263-007-0069-7","volume":"2","author":"JT Hwang","year":"2008","unstructured":"Hwang JT, Kwon DY, Park OJ, et al. Resveratrol protects ROS induced cell death by activating AMPK in H9c2 cardiac muscle cells. Genes Nutr. 2008;2:323\u20136.","journal-title":"Genes Nutr"},{"key":"75_CR80","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/JES.0b013e3182141f80","volume":"39","author":"Z Unqvari","year":"2011","unstructured":"Unqvari Z, Sonntag WE, de Cabo R, et al. Mitochondrial protection by resveratrol. Exerc Sport Sci Rev. 2011;39:128\u201332.","journal-title":"Exerc Sport Sci Rev"},{"key":"75_CR81","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1371\/journal.pbio.0020294","volume":"2","author":"YX Wang","year":"2004","unstructured":"Wang YX, Zhang CL, Yu RT, et al. Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol. 2004;2:e294.","journal-title":"PLoS Biol"},{"key":"75_CR82","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1748-1716.2006.01620.x","volume":"188","author":"DK Kramer","year":"2006","unstructured":"Kramer DK, Ahlsen M, Norrbom J, et al. Human skeletal muscle fibre type variations correlate with PPARa, PPARd and PGC-1a mRNA. Acta Physiol (Oxf). 2006;188:207\u201316.","journal-title":"Acta Physiol (Oxf)"},{"key":"75_CR83","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.cell.2008.06.051","volume":"134","author":"VA Narkar","year":"2008","unstructured":"Narkar VA, Downes M, Yu RT, et al. AMPK and PPAR-\u03b4 agonists are exercise mimetics. Cell. 2008;134:405\u201315.","journal-title":"Cell"},{"key":"75_CR84","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0092-8674(03)00269-1","volume":"113","author":"YX Wang","year":"2003","unstructured":"Wang YX, Lee CH, Tiep S, et al. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell. 2003;113:159\u201379.","journal-title":"Cell"},{"key":"75_CR85","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1743-7075-3-31","volume":"3","author":"G Shailendra","year":"2006","unstructured":"Shailendra G, Ramandeep R, Ehtishamul H, et al. AICAR inhibits adipocyte differentiation in 3T3L1 and restores metabolic alterations in diet-induced obesity mice model. Nutr Metab. 2006;3:31.","journal-title":"Nutr Metab"},{"key":"75_CR86","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nchembio1008-583","volume":"10","author":"K Baar","year":"2008","unstructured":"Baar K, Hardie DG. Small molecules can have big effects on endurance. Nat Chem Biol. 2008;10:583\u20134.","journal-title":"Nat Chem Biol"},{"key":"75_CR87","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1056\/NEJMcibr0806723","volume":"359","author":"LJ Goodyear","year":"2008","unstructured":"Goodyear LJ. The exercise pill; too good to be true? N Engl J Med. 2008;359:1842\u20134.","journal-title":"N Engl J Med"},{"key":"75_CR88","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.cmet.2008.07.004","volume":"2","author":"EA Richter","year":"2008","unstructured":"Richter EA, Kiens B, Wojtaszewski JFP. Can exercise mimetics substitute for exercise? Cell Metab. 2008;2:96\u20138.","journal-title":"Cell Metab"},{"key":"75_CR89","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2165\/11588720-000000000-00000","volume":"41","author":"Z Puthucheary","year":"2011","unstructured":"Puthucheary Z, Skipworth JRA, Rawal J, et al. The ACE gene and human performance 12\u00a0years on. Sports Med. 2011;41:433\u201348.","journal-title":"Sports Med"},{"key":"75_CR90","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2165\/00007256-200838120-00008","volume":"38","author":"P Wang","year":"2008","unstructured":"Wang P, Fedoruk MN, Rupert JL. Keeping pace with ACE. Are ACE inhibitors and angiotensin II type 1 receptor antagonists potential doping agents? Sports Med. 2008;38:1065\u201379.","journal-title":"Sports Med"},{"key":"75_CR91","doi-asserted-by":"crossref","unstructured":"Vaughan D, Huber-Abel FA, Graber F, et al. The angiotensin converting enzyme insertion\/deletion polymorphism alters the response of muscle energy supply lines to exercise. Eur J Appl Physiol. 2013 (Epub 2013 Feb 9).","DOI":"10.1007\/s00421-012-2583-6"},{"key":"75_CR92","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1519\/JSC.0b013e31825bb594","volume":"26","author":"F Sanchis-Gomar","year":"2012","unstructured":"Sanchis-Gomar F, Lippi G. Telmisartan as metabolic modulator: a new perspective in sport doping? J Strength Condit Res. 2012;26:608\u201310.","journal-title":"J Strength Condit Res"},{"key":"75_CR93","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1079\/PNS2004354","volume":"63","author":"SM Machida","year":"2004","unstructured":"Machida SM, Booth FW. Insulin-growth factor 1 and muscle growth: implication for satellite cell proliferation. Proc Nutr Soc. 2004;63:337\u201340.","journal-title":"Proc Nutr Soc"},{"key":"75_CR94","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1083\/jcb.200108071","volume":"157","author":"ER Barton","year":"2002","unstructured":"Barton ER, Morris L, Musaro A, et al. Muscle specific expression of insulin like growth factor 1 counters muscle decline in mdx mice. J Cell Biol. 2002;157:137\u201348.","journal-title":"J Cell Biol"},{"key":"75_CR95","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1152\/japplphysiol.00479.2003","volume":"96","author":"S Lee","year":"2004","unstructured":"Lee S, Barton ER, Sweeney HL, et al. Viral expression of insulin-like growth factor-1 enhances muscle hypertrophy in resistance trained rats. J Appl Physiol. 2004;96:1097\u2013104.","journal-title":"J Appl Physiol"},{"key":"75_CR96","doi-asserted-by":"crossref","first-page":"15603","DOI":"10.1073\/pnas.95.26.15603","volume":"95","author":"ER Barton-Davis","year":"1998","unstructured":"Barton-Davis ER, Shoturma DI, Musaro A, et al. Viral mediated expression of insulin-like growth factor 1 blocks the aging-related loss of skeletal muscle function. Proc Natl Acad Sci USA. 1998;95:15603\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"75_CR97","doi-asserted-by":"crossref","first-page":"9306","DOI":"10.1073\/pnas.151270098","volume":"98","author":"SJ Lee","year":"2001","unstructured":"Lee SJ, McPherron AC. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA. 2001;98:9306\u201311.","journal-title":"Proc Natl Acad Sci USA"},{"key":"75_CR98","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1083\/jcb.200207056","volume":"162","author":"S Mc Croskery","year":"2003","unstructured":"Mc Croskery S, Thomas M, Maxwell L, et al. Myostatin negatively regulates satellite cell activation and self renewal. J Cell Biol. 2003;162:1135\u201347.","journal-title":"J Cell Biol"},{"key":"75_CR99","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.coph.2006.11.011","volume":"7","author":"D Joulia-Ekaza","year":"2007","unstructured":"Joulia-Ekaza D, Cabello G. The myostatin gene: physiology and pharmacological relevance. Curr Opin Pharmacol. 2007;7:310\u20135.","journal-title":"Curr Opin Pharmacol"},{"key":"75_CR100","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/ng0997-71","volume":"17","author":"L Grobet","year":"1997","unstructured":"Grobet L, Martin LJ, Poncelet D, et al. A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. Nat Genet. 1997;17:71\u20134.","journal-title":"Nat Genet"},{"key":"75_CR101","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1101\/gr.7.9.910","volume":"7","author":"R Kambadur","year":"1997","unstructured":"Kambadur R, Sharma M, Smith TP, et al. Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle. Genome Res. 1997;7:910\u20136.","journal-title":"Genome Res"},{"key":"75_CR102","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S0006-291X(02)02953-4","volume":"300","author":"LA Whittemore","year":"2003","unstructured":"Whittemore LA, Song K, Li X, et al. Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem Biophys Res Commun. 2003;300:965\u201371.","journal-title":"Biochem Biophys Res Commun"},{"key":"75_CR103","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1055\/s-2004-830451","volume":"26","author":"PD Matsakas","year":"2005","unstructured":"Matsakas PD, Diel P. The growth factor myostatin, a key regulator in skeletal muscle growth and homeostasis. Int J Sports Med. 2005;26:83\u20139.","journal-title":"Int J Sports Med"},{"key":"75_CR104","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1097\/01.bor.0000184163.61558.ca","volume":"17","author":"KR Wagner","year":"2005","unstructured":"Wagner KR. Muscle regeneration through myostatin inhibition. Curr Opin Rheumatol. 2005;17:720\u20134.","journal-title":"Curr Opin Rheumatol"},{"key":"75_CR105","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1006\/geno.1999.5984","volume":"62","author":"RE Ferrell","year":"1999","unstructured":"Ferrell RE, Conte V, Lawrence EC, et al. Frequent sequence variation in the human myostatin (GDF8) gene as a marker for analysis of muscle related phenotypes. Genomics. 1999;62:203\u20137.","journal-title":"Genomics"},{"key":"75_CR106","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1249\/MSS.0b013e3181930337","volume":"41","author":"MA Kostek","year":"2009","unstructured":"Kostek MA, Angelopoulos TJ, Clarkson PM, et al. Myostatin and follistatin polymorphisms interact with muscle phenotypes and ethnicity. Med Sci Sports Exerc. 2009;41:1063\u201371.","journal-title":"Med Sci Sports Exerc"},{"key":"75_CR107","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa040933","volume":"350","author":"M Schuelke","year":"2004","unstructured":"Schuelke M, Wagner KR, Stolz LE, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med. 2004;350:2682\u20138.","journal-title":"N Engl J Med"},{"key":"75_CR108","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nature01154","volume":"420","author":"S Bogdanovich","year":"2002","unstructured":"Bogdanovich S, Krag TO, Barton ER, et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature. 2002;420:418\u201321.","journal-title":"Nature"},{"key":"75_CR109","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1038\/mtna.2012.15","volume":"1","author":"TC Roberts","year":"2012","unstructured":"Roberts TC, Andaloussi SE, Morris KV, et al. Small RNA-mediated epigenetic myostatin silencing. Mol Ther Nucleic Acids. 2012;1:e23.","journal-title":"Mol Ther Nucleic Acids"},{"key":"75_CR110","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1096\/fj.10-159608","volume":"24","author":"KT Murphy","year":"2010","unstructured":"Murphy KT, Koopman R, Naim T, et al. Antibody-directed myostatin inhibition in 21-mo-old mice reveals novel roles for myostatin signalling in skeletal muscle structure and function. FASEB J. 2010;24:4433\u201342.","journal-title":"FASEB J"},{"key":"75_CR111","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1600-0838.2007.00759.x","volume":"18","author":"MN Fedoruk","year":"2008","unstructured":"Fedoruk MN, Rupert JL. Myostatin inhibition: a potential performance enhancement strategy? Scand J Med Sci Sports. 2008;18:123.","journal-title":"Scand J Med Sci Sports"},{"key":"75_CR112","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1161\/01.CIR.98.25.2800","volume":"98","author":"DW Losordo","year":"1998","unstructured":"Losordo DW, Vale PR, Symes JF, et al. Gene therapy for myocardial angiogenesis. Initial clinical results with direct myocardial injection of phVEGF(165) as sole therapy for myocardial ischemia. Circulation. 1998;98:2800\u20134.","journal-title":"Circulation"},{"key":"75_CR113","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/01.CIR.0000093398.16124.29","volume":"108","author":"S Rajagopalan","year":"2003","unstructured":"Rajagopalan S, Mohler ER, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomised, double blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation. 2003;108:1933\u20138.","journal-title":"Circulation"},{"key":"75_CR114","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S1043-0679(03)70003-3","volume":"15","author":"JL Yeh","year":"2003","unstructured":"Yeh JL, Giordano FJ. Gene-based therapeutic angiogenesis. Semin Thorac Cardiovasc Surg. 2003;15:236\u201349.","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"75_CR115","first-page":"1","volume":"1","author":"AA Fallahi","year":"2011","unstructured":"Fallahi AA, Ravasi AA, Farhud DD. Genetic doping and health damages. Iranian J Publ Health. 2011;1:1\u201314.","journal-title":"Iranian J Publ Health"},{"key":"75_CR116","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1126\/science.288.5466.669","volume":"288","author":"M Cavazzana-Calvo","year":"2000","unstructured":"Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000;288:669\u201372.","journal-title":"Science"},{"key":"75_CR117","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJMoa012616","volume":"346","author":"S Hacein-Bey-Abina","year":"2002","unstructured":"Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 2002;346:1185\u201393.","journal-title":"N Engl J Med"},{"key":"75_CR118","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","volume":"118","author":"S Hacein-Bey-Abina","year":"2008","unstructured":"Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008;118:3132\u201342.","journal-title":"J Clin Invest"},{"key":"75_CR119","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","volume":"80","author":"SE Raper","year":"2003","unstructured":"Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 2003;80:148\u201358.","journal-title":"Mol Genet Metab"},{"key":"75_CR120","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ghir.2006.09.006","volume":"16","author":"JK Perry","year":"2006","unstructured":"Perry JK, Emerald BS, Mertani HC, et al. The oncogenic potential of growth hormone. Growth Horm IGF Res. 2006;16:277\u201389.","journal-title":"Growth Horm IGF Res"},{"key":"75_CR121","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/PHM.0b013e318198b622","volume":"88","author":"S Horn","year":"2009","unstructured":"Horn S, Gregory P, Guskiewicz KM. Self-reported anabolic-androgenic steroids use and musculoskeletal injuries: findings from the center for the study of retired athletes health survey of retired NFL players. Am J Phys Med Rehabil. 2009;88:192\u2013200.","journal-title":"Am J Phys Med Rehabil."},{"key":"75_CR122","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1055\/s-2006-923986","volume":"27","author":"HJ Haisma","year":"2006","unstructured":"Haisma HJ, de Hon O. Gene doping. Int J Sports Med. 2006;27:257\u201366.","journal-title":"Int J Sports Med"},{"key":"75_CR123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2660(06)51001-6","volume":"51","author":"AJ Schneider","year":"2006","unstructured":"Schneider AJ, Friedmann T. Gene doping in sports: the science and ethics of genetically modified athletes. Adv Genet. 2006;51:1\u2013110.","journal-title":"Adv Genet"},{"key":"75_CR124","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jgm.1114","volume":"10","author":"A Baoutina","year":"2008","unstructured":"Baoutina A, Alexander IE, Rasko JE, et al. Developing strategies for detection of gene doping. J Gene Med. 2008;10:3\u201320.","journal-title":"J Gene Med"},{"key":"75_CR125","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/gt.2011.19","volume":"18","author":"W Ni","year":"2011","unstructured":"Ni W, Le Guiner C, Gernoux G, et al. Longevity of rAAV vector and plasmid DNA in blood after intramuscular injection in nonhuman primates: implications for gene doping. Gene Ther. 2011;18:709\u201318.","journal-title":"Gene Ther"},{"issue":"5","key":"75_CR126","doi-asserted-by":"crossref","first-page":"e36461","DOI":"10.1371\/journal.pone.0036461","volume":"7","author":"W Ni","year":"2012","unstructured":"Ni W, Le Guiner C, Moullier P, et al. Development and utility of an internal threshold control (ITC) real-time PCR assay for exogenous DNA detection. PLoS One. 2012;7(5):e36461.","journal-title":"PLoS One."},{"key":"75_CR127","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/gt.2010.122","volume":"18","author":"T Beiter","year":"2011","unstructured":"Beiter T, Zimmermann M, Fragasso A, et al. Direct and long-term detection of gene doping in conventional blood samples. Gene Ther. 2011;18:225\u201331.","journal-title":"Gene Ther"},{"key":"75_CR128","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/gt.2010.49","volume":"17","author":"A Baoutina","year":"2010","unstructured":"Baoutina A, Coldham T, Bains GS, et al. Gene doping detection: evaluation of approach for direct detection of gene transfer using erythropoietin. Gene Ther. 2010;17:1022\u201332.","journal-title":"Gene Ther"},{"key":"75_CR129","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/sj.gt.3302191","volume":"11","author":"JJ Min","year":"2004","unstructured":"Min JJ, Gambhir SS. Gene therapy progress and prospects: noninvasive imaging of gene therapy in living subjects. Gene Ther. 2004;11:115\u201325.","journal-title":"Gene Ther"},{"key":"75_CR130","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/FTD.0b013e31811f3af6","volume":"29","author":"J Segura","year":"2007","unstructured":"Segura J, Fillat C, Andreu D, et al. Monitoring gene therapy by external imaging of mRNA: pilot study on murine erythropoietin. Ther Drug Monit. 2007;29:612\u20138.","journal-title":"Ther Drug Monit"},{"key":"75_CR131","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/jms.1584","volume":"44","author":"M Thevis","year":"2009","unstructured":"Thevis M, Thomas A, Kohler M, et al. Emerging drugs: mechanism of action, mass spectrometry and doping control analysis. J Mass Spectrom. 2009;44:442\u201360.","journal-title":"J Mass Spectrom"},{"key":"75_CR132","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/rcm.3987","volume":"23","author":"M Thevis","year":"2009","unstructured":"Thevis M, Beuck S, Thomas A, et al. Doping control analysis of emerging drugs in human plasma\u2014identification of GW501516. S-107, JTV-519, and S-40503. Rapid Commun Mass Spectrom. 2009;23:1139.","journal-title":"Rapid Commun Mass Spectrom"},{"key":"75_CR133","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1007\/s00216-009-3283-x","volume":"396","author":"M Thevis","year":"2010","unstructured":"Thevis M, M\u00f6ller I, Thomas A, et al. Characterization of two major urinary metabolites of the PPARdelta-agonist GW1516 and implementation of the drug in routine doping controls. Anal Bioanal Chem. 2010;396:2479\u201391.","journal-title":"Anal Bioanal Chem."},{"key":"75_CR134","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/dta.1413","volume":"4","author":"T Sobolevsky","year":"2012","unstructured":"Sobolevsky T, Dikunets M, Sukhanova I, et al. Detection of PPAR\u03b4 agonists GW1516 and GW0742 and their metabolites in human urine. Drug Test Anal. 2012;4:754\u201360.","journal-title":"Drug Test Anal."},{"key":"75_CR135","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1007\/s00216-010-3560-8","volume":"396","author":"A Thomas","year":"2010","unstructured":"Thomas A, Beuck S, Eickhoff JC, et al. Quantification of urinary AICAR concentrations as a matter of doping controls. Anal Bioanal Chem. 2010;396:2899\u2013908.","journal-title":"Anal Bioanal Chem"},{"key":"75_CR136","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/dta.283","volume":"3","author":"M Thevis","year":"2011","unstructured":"Thevis M, Geyer H, Thomas A, et al. Trafficking of drug candidates relevant for sports drug testing: detection of non-approved therapeutics categorized as anabolic and gene doping agents in products distributed via the internet. Drug Test Anal. 2011;3:331\u20136.","journal-title":"Drug Test Anal"},{"key":"75_CR137","first-page":"153","volume-title":"From birth to death and bench to clinic: the Hastings Center bioethics briefing book","author":"TH Murray","year":"2008","unstructured":"Murray TH. Sport enhancement. In: Mary C, editor. From birth to death and bench to clinic: the Hastings Center bioethics briefing book. Garrison: The Hastings Center; 2008. p. 153\u20138."}],"container-title":["Sports Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40279-013-0075-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40279-013-0075-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40279-013-0075-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T13:13:08Z","timestamp":1645967588000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40279-013-0075-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,6]]},"references-count":137,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["75"],"URL":"https:\/\/doi.org\/10.1007\/s40279-013-0075-4","relation":{},"ISSN":["0112-1642","1179-2035"],"issn-type":[{"value":"0112-1642","type":"print"},{"value":"1179-2035","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,6]]}}}